Cancer

Should we rename low risk cancers?

Should we rename low risk ("indolent") cancers in a bid to reduce anxiety and harm from unnecessary investigation and treatment? Experts debate the issue in The BMJ today.

Cancer

Thirty percent fewer prostate cancer deaths with PSA screening

PSA screening cuts deaths from prostate cancer by some 30 percent. This research was based on data of 20,000 men monitored for more than two decades. The men's initially measured PSA levels proved highly significant as a ...

Cancer

Targeted treatment shrinks deadly pediatric brain tumors

Chemotherapy and radiation are effective cancer treatments because they kill rapidly dividing cells, including tumor cells. But for children—whose tiny bodies are still growing—these treatments can cause lifelong damage. ...

page 1 from 3